胃复春治疗慢性萎缩性胃炎疗效与安全性的网状Meta分析
本研究采用网状Meta分析系统评价中成药胃复春治疗慢性萎缩性胃炎(CAG)的疗效与安全性,共纳入38项随机对照试验、3844例受试者,涉及10种干预措施。结果显示胃复春联合黏膜保护剂在总体临床疗效排名最高,联合促动力药在恢复胃泌素/胃动素水平及缓解症状负担方面最优;胃复春单药在多项结局上优于部分西药,联合用药不良事件少于单药治疗。
要点
- 胃复春联合黏膜保护剂在总体临床疗效上排名最高。
- 胃复春联合促动力药对恢复GAS/MTL水平及缓解症状最优。
- 胃复春联合抑酸药或促动力药不良事件少于单药治疗。
核心结论
- 胃复春尤其联合西药可提高CAG患者临床疗效并降低不良事件发生率,支持其作为改善CAG临床结局的治疗选择。
研究设计与样本
- 系统检索比较胃复春与其他干预治疗CAG的随机对照试验,进行网状Meta分析,方案在PROSPERO注册(CRD420251056533)。
- 共纳入38项RCT、3844例受试者,评估10种干预:常规治疗、促动力药、黏膜保护剂、抑酸药、幽门螺杆菌根除治疗、胃复春、胃复春+促动力药、胃复春+黏膜保护剂、胃复春+抑酸药、胃复春+幽门螺杆菌根除治疗。
- 采用Cochrane手册与GRADEpro评估偏倚风险,二分类结局计算风险比,连续变量采用标准化均数差及95%CI,并绘制漏斗图评估发表偏倚、以SUCRA排序,使用STATA 15.0与Review Manager 5.3分析。
主要发现
- 多数纳入研究在随机化、失访、报告等域评为低偏倚风险,分配隐藏与盲法偏倚风险仍不明确。
- 敏感性分析显示剔除任一单项研究对总体合并结果影响极小,统计异质性可忽略。
- 网状Meta分析显示胃复春联合黏膜保护剂在总体临床疗效排名最高。
- 胃复春联合促动力药在恢复胃泌素(GAS)/胃动素(MTL)水平及减轻症状负担方面最有效。
- 胃复春单药在多项结局上优于黏膜保护剂、抑酸剂及常规治疗等部分西药,联合抑酸药或促动力药不良事件少于单药治疗。
关键数值与推荐
- 临床疗效、胃肠道症状评分、胃肠道激素水平及不良反应为评估结局。
- 二分类结局采用风险比,连续变量采用标准化均数差及95%CI。
- 采用SUCRA对干预措施排序。
临床怎么用
- CAG患者可考虑胃复春为基础治疗,联合黏膜保护剂以提升总体临床疗效。
- 以恢复GAS/MTL水平或减轻症状负担为目标时,可优先考虑胃复春联合促动力药。
- 联用抑酸药或促动力药可能减少不良事件,但需结合患者个体情况。
局限性
- 纳入研究在分配隐藏与盲法方面偏倚风险不明确。
- 原文未报告具体不良事件类型与发生率。
- 原文未报告各干预措施的具体效应量数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic atrophic gastritis (CAG) is a chronic condition characterized by a reduction in gastric mucosal glands and is often regarded as a precursor to gastric cancer. Currently, Western medicine lacks specific treatments for CAG, with management primarily focusing on symptomatic relief and, in cases involving Helicobacter pylori infection, eradication therapy. This study employs a network meta-analysis (NMA) to evaluate the efficacy and safety of the Chinese patent medicine Wei-Fu-Chun (WFC) in the treatment of CAG. METHODS: We systematically reviewed randomized controlled trials (RCTs) comparing WFC with other interventions for CAG. The outcomes assessed included clinical effectiveness, gastrointestinal symptom scores, gastrointestinal hormone levels, and adverse reactions. The quality of the included studies was assessed with the Cochrane Handbook and GRADEpro software based on the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, and selective reporting. Risk ratios were calculated for dichotomous outcomes, and standardized mean differences with 95% confidence intervals were used for continuous variables. Funnel plots were generated to assess publication bias, and treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Data analysis was performed using STATA 15.0 and Review Manager 5.3. The protocol has been registered with PROSPERO under the registration number CRD420251056533. RESULTS: A total of 38 RCTs involving 3,844 participants were included, and 10 interventions were evaluated: conventional therapy, prokinetics, mucosal-protective agents (MPAs), acid-suppressing drugs (ASDs), H. pylori eradication therapy (HET), WFC, WFC + prokinetics, WFC + MPAs, WFC + ASDs, and WFC + HET. The majority of the included studies were evaluated as having a low risk of bias regarding randomization, attrition, reporting, and other domains, while the risk of bias remained unclear for allocation concealment and blinding. Sensitivity analysis revealed that excluding any single study had a minimal influence on the overall pooled results, and statistical heterogeneity was negligible. The NMA results indicated that WFC combined with MPA ranked the highest in overall clinical efficacy, while WFC combined with prokinetics was the most effective in restoring gastrin (GAS)/motilin (MTL) levels and alleviating symptom burden. WFC monotherapy also outperformed several Western medications (e.g., MPA, acid inhibitors, and conventional therapy) across multiple outcomes. Combinations of WFC with acid suppressants or prokinetics were associated with fewer adverse events than monotherapies, suggesting a potential reduction in drug-related side effects. CONCLUSION: WFC, particularly in combination with Western medications, enhances clinical efficacy and reduces the incidence of adverse events in patients with CAG. These findings support its potential as a therapeutic option for improving clinical outcomes in CAG. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251056533.
引用
- Wu Y, Hu L. Therapeutic effect and safety of Wei-Fu-Chun in the treatment of chronic atrophic gastritis: a network meta-analysis. Front Pharmacol. 2025. PMID: 41357878. doi:10.3389/fphar.2025.1693427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。